SEOUL -- Samsung Biologics closed $1.5 billion worth of orders in the past three months, as the world's leading contract biopharmaceutical manufacturer topped its sales for all of 2019 by 150% due to the coronavirus pandemic.
Pharmaceuticals
Samsung Biologics snags $1.5bn in orders on pandemic rush
South Korean drug-making powerhouse sees stock price double this year
